BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)

  June 2, 2025

   · 

  8 min read
• Press Releases

  BiVACOR’s Total Artificial Heart Receives FDA Breakthrough Device Designation

  June 2, 2025

   · 

  3 min read
• Press Releases

  HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options

  June 2, 2025

   · 

  6 min read
• Press Releases

  Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

  June 2, 2025

   · 

  22 min read
• Press Releases

  Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE

  June 2, 2025

   · 

  6 min read
• Press Releases

  Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

  June 2, 2025

   · 

  21 min read
• Press Releases

  Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

  June 2, 2025

   · 

  17 min read
• Press Releases

  Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma

  June 2, 2025

   · 

  10 min read
• Press Releases

  New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer

  June 2, 2025

   · 

  10 min read
• Press Releases

  Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

  June 2, 2025

   · 

  14 min read